Is Tharimmune Stock a Good Investment?
Tharimmune Investment Advice | THAR |
- Examine Tharimmune's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Tharimmune's leadership team and their track record. Good management can help Tharimmune navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceutical Products space and any emerging trends that could impact Tharimmune's business and its evolving consumer preferences.
- Compare Tharimmune's performance and market position to its competitors. Analyze how Tharimmune is positioned in terms of product offerings, innovation, and market share.
- Check if Tharimmune pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Tharimmune's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Tharimmune stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Tharimmune is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Tharimmune Stock
Researching Tharimmune's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book ratio of 0.91. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tharimmune recorded earning per share (EPS) of 61.01. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 28th of May 2024.
To determine if Tharimmune is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Tharimmune's research are outlined below:
| Tharimmune generated a negative expected return over the last 90 days | |
| Tharimmune may become a speculative penny stock | |
| Tharimmune has high historical volatility and very poor performance | |
| Tharimmune has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (9.32 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tharimmune generates negative cash flow from operations |
Tharimmune uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Tharimmune. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Tharimmune's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 27th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Tharimmune's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.75 M.Basic technical analysis of Tharimmune Stock
As of the 20th of March, Tharimmune has the Coefficient Of Variation of (852.96), variance of 16.35, and Risk Adjusted Performance of (0.1). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tharimmune, as well as the relationship between them. Please validate Tharimmune mean deviation, treynor ratio, as well as the relationship between the Treynor Ratio and kurtosis to decide if Tharimmune is priced more or less accurately, providing market reflects its prevalent price of 1.55 per share. Please also confirm Tharimmune jensen alpha, which is currently at (0.46) to double-check the company can sustain itself at a future point.Tharimmune's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tharimmune insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tharimmune's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tharimmune insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Appajosyula Sireesh over two months ago Acquisition by Appajosyula Sireesh of 52875 shares of Tharimmune at 1.93 subject to Rule 16b-3 | ||
Milby Randy over three months ago Acquisition by Milby Randy of 4600 shares of Tharimmune at 2.12 subject to Rule 16b-3 | ||
Parikh Sanam over three months ago Insider Trading | ||
Bui Lynne A. over six months ago Acquisition by Bui Lynne A. of 2353 shares of Tharimmune at 2.925 subject to Rule 16b-3 | ||
Milby Randy over a year ago Purchase by Milby Randy of 29000 shares of Tharimmune | ||
Milby Randy over a year ago Purchase by Milby Randy of 10000 shares of Tharimmune |
Understand Tharimmune's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Tharimmune's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.1) | |||
| Market Risk Adjusted Performance | (1.54) | |||
| Mean Deviation | 2.85 | |||
| Coefficient Of Variation | (852.96) | |||
| Standard Deviation | 4.04 | |||
| Variance | 16.35 | |||
| Information Ratio | (0.10) | |||
| Jensen Alpha | (0.46) | |||
| Total Risk Alpha | (0.14) | |||
| Treynor Ratio | (1.55) | |||
| Maximum Drawdown | 24.57 | |||
| Value At Risk | (5.85) | |||
| Potential Upside | 6.67 | |||
| Skewness | (1.09) | |||
| Kurtosis | 3.81 |
| Risk Adjusted Performance | (0.1) | |||
| Market Risk Adjusted Performance | (1.54) | |||
| Mean Deviation | 2.85 | |||
| Coefficient Of Variation | (852.96) | |||
| Standard Deviation | 4.04 | |||
| Variance | 16.35 | |||
| Information Ratio | (0.10) | |||
| Jensen Alpha | (0.46) | |||
| Total Risk Alpha | (0.14) | |||
| Treynor Ratio | (1.55) | |||
| Maximum Drawdown | 24.57 | |||
| Value At Risk | (5.85) | |||
| Potential Upside | 6.67 | |||
| Skewness | (1.09) | |||
| Kurtosis | 3.81 |
Consider Tharimmune's intraday indicators
Tharimmune intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Tharimmune stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Tharimmune time-series forecasting models is one of many Tharimmune's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Tharimmune's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Tharimmune Stock media impact
Far too much social signal, news, headlines, and media speculation about Tharimmune that are available to investors today. That information is available publicly through Tharimmune media outlets and privately through word of mouth or via Tharimmune internal channels. However, regardless of the origin, that massive amount of Tharimmune data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Tharimmune news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Tharimmune relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Tharimmune's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Tharimmune alpha.
Additional Tools for Tharimmune Stock Analysis
When running Tharimmune's price analysis, check to measure Tharimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tharimmune is operating at the current time. Most of Tharimmune's value examination focuses on studying past and present price action to predict the probability of Tharimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tharimmune's price. Additionally, you may evaluate how the addition of Tharimmune to your portfolios can decrease your overall portfolio volatility.